Stock ELAN ELANCO ANIMAL HEALTH INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Elanco Animal Health Incorporated

Equities

ELAN

US28414H1032

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-26 pm EDT 		5-day change 1st Jan Change
13.26 USD +1.69% Intraday chart for Elanco Animal Health Incorporated +2.39% -11.01%
Apr. 01 Elanco Animal Health Appoints Two Ancora Holdings' Nominees to Board MT
Apr. 01 Elanco appoints two directors after settling with activist Ancora RE

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 10,985 14,474 13,427 5,795 7,343 6,537 - -
Enterprise Value (EV) 1 13,006 20,106 19,108 11,350 12,765 11,532 11,061 10,542
P/E ratio 164 x -24.1 x -29.3 x -81.5 x -5.96 x -177 x 61.2 x 27.6 x
Yield - - - - - - - -
Capitalization / Revenue 3.58 x 4.42 x 2.82 x 1.31 x 1.66 x 1.46 x 1.4 x 1.34 x
EV / Revenue 4.24 x 6.14 x 4.01 x 2.57 x 2.89 x 2.57 x 2.38 x 2.17 x
EV / EBITDA 19.6 x 38 x 18.1 x 11.1 x 13 x 11.7 x 10.4 x 9.22 x
EV / FCF 155 x -114 x 53.5 x 36 x 97.4 x 19.4 x 14.7 x 14.9 x
FCF Yield 0.64% -0.87% 1.87% 2.78% 1.03% 5.15% 6.8% 6.73%
Price to Book 1.98 x 1.71 x 1.78 x 0.77 x 1.18 x 1.06 x 1.05 x -
Nbr of stocks (in thousands) 373,004 471,915 473,099 474,205 492,798 492,970 - -
Reference price 2 29.45 30.67 28.38 12.22 14.90 13.26 13.26 13.26
Announcement Date 2/19/20 2/24/21 2/24/22 2/21/23 2/26/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 3,071 3,273 4,765 4,418 4,417 4,492 4,655 4,863
EBITDA 1 662.8 528.5 1,057 1,023 979 987 1,061 1,143
EBIT 1 548.8 213.5 922 918 876 858.7 942.7 1,021
Operating Margin 17.87% 6.52% 19.35% 20.78% 19.83% 19.12% 20.25% 20.99%
Earnings before Tax (EBT) 1 - - - - - 1,248 1,463 777.5
Net income 1 67.9 -560.1 -472 -74 -1,231 -36.25 59.37 126.2
Net margin 2.21% -17.11% -9.91% -1.67% -27.87% -0.81% 1.28% 2.59%
EPS 2 0.1800 -1.270 -0.9700 -0.1500 -2.500 -0.0750 0.2167 0.4800
Free Cash Flow 1 83.7 -175.6 357 315 131 593.7 751.7 709.6
FCF margin 2.73% -5.36% 7.49% 7.13% 2.97% 13.22% 16.15% 14.59%
FCF Conversion (EBITDA) 12.63% - 33.77% 30.79% 13.38% 60.15% 70.84% 62.09%
FCF Conversion (Net income) 123.27% - - - - - 1,266.24% 562.43%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/19/20 2/24/21 2/24/22 2/21/23 2/26/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 1,131 1,113 1,225 1,177 1,028 988 1,257 1,057 1,068 1,035 1,175 1,158 1,093 1,074 1,226
EBITDA 1 211 212 339 300 205 174 379 222 214 165 264.5 262.2 228.7 232.1 305.9
EBIT 1 194 180 315 284 180 157 354 210 183 148 242.2 230.4 198.5 197.7 286.1
Operating Margin 17.15% 16.17% 25.71% 24.13% 17.51% 15.89% 28.16% 19.87% 17.13% 14.3% 20.62% 19.9% 18.16% 18.41% 23.33%
Earnings before Tax (EBT) - - - - - - - - - - - - - - -
Net income 1 -104 -97 48 -22 -49 -54 103 -97 -1,096 -141 -19.4 -0.85 -17.3 -6.95 46
Net margin -9.2% -8.72% 3.92% -1.87% -4.77% -5.47% 8.19% -9.18% -102.62% -13.62% -1.65% -0.07% -1.58% -0.65% 3.75%
EPS 2 -0.2100 -0.2000 0.1000 -0.0400 -0.1000 -0.1100 0.2100 -0.2000 -2.220 -0.2900 -0.0233 0.006670 -0.0367 -0.0233 0.0750
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/5/21 2/24/22 5/9/22 8/8/22 11/8/22 2/21/23 5/9/23 8/7/23 11/7/23 2/26/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 2,021 5,632 5,681 5,555 5,422 4,847 4,352 3,791
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 3.049 x 10.66 x 5.375 x 5.43 x 5.538 x 4.911 x 4.101 x 3.318 x
Free Cash Flow 1 83.7 -176 357 315 131 577 746 692
ROE (net income / shareholders' equity) 7.33% 2.95% 6.42% 7.41% 6.5% 7.64% 8.34% 8.64%
ROA (Net income/ Total Assets) 4.39% 1.55% 3.01% 3.43% 2.94% 3.13% 3.75% 4.22%
Assets 1 1,546 -36,145 -15,692 -2,159 -41,855 -895.7 2,208 3,356
Book Value Per Share 2 14.90 18.00 15.90 15.90 12.60 12.50 12.70 13.30
Cash Flow per Share 2 0.6100 -0.0900 0.9900 0.9300 0.5500 1.190 1.540 1.760
Capex 1 140 135 126 137 140 174 199 206
Capex / Sales 4.57% 4.11% 2.64% 3.1% 3.17% 3.87% 4.27% 4.24%
Announcement Date 2/19/20 2/24/21 2/24/22 2/21/23 2/26/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Elanco Animal Health Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
13.26 USD
Average target price
17.24 USD
Spread / Average Target
+29.98%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Veterinary Drugs

1st Jan change Capi.
ELANCO ANIMAL HEALTH INCORPORATED Stock Elanco Animal Health Incorporated
-11.01% 6.54B
ZOETIS INC. Stock Zoetis Inc.
-19.73% 72.39B
BLUESTAR ADISSEO COMPANY Stock Bluestar Adisseo Company
+15.88% 3.43B
VIRBAC Stock Virbac
-2.92% 3.12B
VIMIAN GROUP AB Stock Vimian Group AB
-0.68% 1.4B
JINYU BIO-TECHNOLOGY CO., LTD. Stock Jinyu Bio-technology Co., Ltd.
-17.27% 1.34B
VETOQUINOL SA Stock Vetoquinol SA
-2.73% 1.26B
WUHAN KEQIAN BIOLOGY CO.,LTD Stock Wuhan Keqian Biology Co.,Ltd
-14.67% 1.12B
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD. Stock Tianjin Ringpu Bio-Technology Co.,Ltd.
-5.37% 990M
PULIKE BIOLOGICAL ENGINEERING, INC. Stock Pulike Biological Engineering, Inc.
-24.06% 805M
Veterinary Drugs
  1. Stock Market
  2. Equities
  3. ELAN Stock
  4. Financials Elanco Animal Health Incorporated